Historical Valuation
ANI Pharmaceuticals Inc (ANIP) is now in the Undervalued zone, suggesting that its current forward PE ratio of 9.96 is considered Undervalued compared with the five-year average of 12.89. The fair price of ANI Pharmaceuticals Inc (ANIP) is between 89.69 to 139.19 according to relative valuation methord. Compared to the current price of 76.28 USD , ANI Pharmaceuticals Inc is Undervalued By 14.95%.
Relative Value
Fair Zone
89.69-139.19
Current Price：76.28
14.95%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
ANI Pharmaceuticals Inc (ANIP) has a current Price-to-Book (P/B) ratio of 3.24. Compared to its 3-year average P/B ratio of 2.82 , the current P/B ratio is approximately 14.95% higher. Relative to its 5-year average P/B ratio of 2.47, the current P/B ratio is about 31.25% higher. ANI Pharmaceuticals Inc (ANIP) has a Forward Free Cash Flow (FCF) yield of approximately 9.50%. Compared to its 3-year average FCF yield of 5.35%, the current FCF yield is approximately 77.41% lower. Relative to its 5-year average FCF yield of 2.49% , the current FCF yield is about 280.96% lower.
P/B
Median3y
2.82
Median5y
2.47
FCF Yield
Median3y
5.35
Median5y
2.49
Competitors Valuation Multiple
AI Analysis for ANIP
The average P/S ratio for ANIP competitors is 101.67, providing a benchmark for relative valuation. ANI Pharmaceuticals Inc Corp (ANIP.O) exhibits a P/S ratio of 1.79, which is -98.23% above the industry average. Given its robust revenue growth of 53.58%, this premium appears sustainable.
Performance Decomposition
AI Analysis for ANIP
1Y
3Y
5Y
Market capitalization of ANIP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ANIP in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ANIP currently overvalued or undervalued?
ANI Pharmaceuticals Inc (ANIP) is now in the Undervalued zone, suggesting that its current forward PE ratio of 9.96 is considered Undervalued compared with the five-year average of 12.89. The fair price of ANI Pharmaceuticals Inc (ANIP) is between 89.69 to 139.19 according to relative valuation methord. Compared to the current price of 76.28 USD , ANI Pharmaceuticals Inc is Undervalued By 14.95% .
What is ANI Pharmaceuticals Inc (ANIP) fair value?
ANIP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of ANI Pharmaceuticals Inc (ANIP) is between 89.69 to 139.19 according to relative valuation methord.
How does ANIP's valuation metrics compare to the industry average?
The average P/S ratio for ANIP's competitors is 101.67, providing a benchmark for relative valuation. ANI Pharmaceuticals Inc Corp (ANIP) exhibits a P/S ratio of 1.79, which is -98.23% above the industry average. Given its robust revenue growth of 53.58%, this premium appears sustainable.
What is the current P/B ratio for ANI Pharmaceuticals Inc (ANIP) as of Jan 11 2026?
As of Jan 11 2026, ANI Pharmaceuticals Inc (ANIP) has a P/B ratio of 3.24. This indicates that the market values ANIP at 3.24 times its book value.
What is the current FCF Yield for ANI Pharmaceuticals Inc (ANIP) as of Jan 11 2026?
As of Jan 11 2026, ANI Pharmaceuticals Inc (ANIP) has a FCF Yield of 9.50%. This means that for every dollar of ANI Pharmaceuticals Inc’s market capitalization, the company generates 9.50 cents in free cash flow.
What is the current Forward P/E ratio for ANI Pharmaceuticals Inc (ANIP) as of Jan 11 2026?
As of Jan 11 2026, ANI Pharmaceuticals Inc (ANIP) has a Forward P/E ratio of 9.96. This means the market is willing to pay $9.96 for every dollar of ANI Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for ANI Pharmaceuticals Inc (ANIP) as of Jan 11 2026?
As of Jan 11 2026, ANI Pharmaceuticals Inc (ANIP) has a Forward P/S ratio of 1.79. This means the market is valuing ANIP at $1.79 for every dollar of expected revenue over the next 12 months.